Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics

May, Megan Brafford; Glode, Ashley E.

doi:10.2147/cmar.s81425

Cited by 33 publications

(19 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Dronabinol (synthetic delta-9-tetrahydrocannabinol) was approved as an orphan drug for AIDSrelated anorexia in 1985 and is now also approved for cancer chemotherapy related nausea and vomiting (Brafford May and Glode, 2016). Xyrem (sodium g-hydroxybutyrate) was approved for the treatment of cataplexy associated with narcolepsy in 2004 (Owen, 2008).…”

Section: Schedule Imentioning

confidence: 99%

Psychiatry & the psychedelic drugs. Past, present & future

2018

View full text Add to dashboard Cite

a b s t r a c tThe classical psychedelic drugs, including psilocybin, lysergic acid diethylamide and mescaline, were used extensively in psychiatry before they were placed in Schedule I of the UN Convention on Drugs in 1967. Experimentation and clinical trials undertaken prior to legal sanction suggest that they are not helpful for those with established psychotic disorders and should be avoided in those liable to develop them. However, those with so-called 'psychoneurotic' disorders sometimes benefited considerably from their tendency to 'loosen' otherwise fixed, maladaptive patterns of cognition and behaviour, particularly when given in a supportive, therapeutic setting. Pre-prohibition studies in this area were sub-optimal, although a recent systematic review in unipolar mood disorder and a meta-analysis in alcoholism have both suggested efficacy. The incidence of serious adverse events appears to be low. Since 2006, there have been several pilot trials and randomised controlled trials using psychedelics (mostly psilocybin) in various non-psychotic psychiatric disorders. These have provided encouraging results that provide initial evidence of safety and efficacy, however the regulatory and legal hurdles to licensing psychedelics as medicines are formidable. This paper summarises clinical trials using psychedelics pre and post prohibition, discusses the methodological challenges of performing good quality trials in this area and considers a strategic approach to the legal and regulatory barriers to licensing psychedelics as a treatment in mainstream psychiatry.

show abstract

Section: Schedule Imentioning

confidence: 99%

Psychiatry & the psychedelic drugs. Past, present & future

2018

View full text Add to dashboard Cite

show abstract

“…According to studies, the incidence of nausea and vomiting can be reduced by activating the CB 1 receptor with THC [ 113 ]. As a result of receptor stimulation, the proemetic effects of dopamine and serotonin are abolished [ 114 ]. In the fight against CINV, oral cannabinoid preparations are more effective than a placebo.…”

Section: Pharmacological Applicationmentioning

confidence: 99%

Cannabis sativa L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment

Stasiłowicz

Tomala

Podolak

et al. 2021

IJMS

View full text Add to dashboard Cite

Cannabis sativa L. turned out to be a valuable source of chemical compounds of various structures, showing pharmacological activity. The most important groups of compounds include phytocannabinoids and terpenes. The pharmacological activity of Cannabis (in epilepsy, sclerosis multiplex (SM), vomiting and nausea, pain, appetite loss, inflammatory bowel diseases (IBDs), Parkinson’s disease, Tourette’s syndrome, schizophrenia, glaucoma, and coronavirus disease 2019 (COVID-19)), which has been proven so far, results from the affinity of these compounds predominantly for the receptors of the endocannabinoid system (the cannabinoid receptor type 1 (CB1), type two (CB2), and the G protein-coupled receptor 55 (GPR55)) but, also, for peroxisome proliferator-activated receptor (PPAR), glycine receptors, serotonin receptors (5-HT), transient receptor potential channels (TRP), and GPR, opioid receptors. The synergism of action of phytochemicals present in Cannabis sp. raw material is also expressed in their increased bioavailability and penetration through the blood–brain barrier. This review provides an overview of phytochemistry and pharmacology of compounds present in Cannabis extracts in the context of the current knowledge about their synergistic actions and the implications of clinical use in the treatment of selected diseases.

show abstract

“…En el último grupo hay agonistas CB como el HY-210, el DHM-cannabidiol, la nabilona y el dronabinol. Los dos últimos han sido estudiados en dolor y nauseas por quimioterapia (13,25,26). Dentro de los antagonistas del receptor CB1 se destaca el rimonabant, estudiado en obesidad y cesación tabáquica (27).…”

Section: Cannabinoidesunclassified

Sistema endocannabinoide y el rol del cannabis medicinal en el tratamiento de la espasticidad: una revisión narrativa

Navarro

2022

Iatreia

View full text Add to dashboard Cite

Hasta la fecha se han identificado más de 500 fitocannabinnoides derivados de la planta de Cannabis sativa, entre los cuales los más importantes son el ∆9-tetra-hidrocannabinol (THC) y el cannabidiol (CBD). Ambas moléculas interactúan con el sistema endocannabinoide y generan un efecto terapéutico en diferentes desórdenes neurológicos, dentro de los cuales se incluye la espasticidad. El mecanismo de acción postulado considera que el THC modula la hiperexcitabilidad de la neurona motora inferior, lo que provoca una disminución en el tono muscular, mientras que el CBD genera un efecto antiinflamatorio que contribuye a reducir el dolor. El uso terapéutico de estas moléculas en sujetos con espasticidad refractaria causada por diferentes etiologías ha permitido la mejoría de síntomas como los calambres, el dolor y el insomnio, lo que a su vez ha llevado a disminuir la dosis de fármacos antiespásticos y analgésicos. Esta revisión narrativa pretende ilustrar brevemente a la comunidad hispanohablante la fisiología del sistema endocannabinoide, la farmacología de los cannabinoides y su forma de uso, y sintetiza la información más relevante de los estudios que sugieren que estas moléculas son una potencial terapia en espasticidad refractaria.

show abstract

Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics

Cited by 33 publications

References 14 publications

Psychiatry & the psychedelic drugs. Past, present & future

Psychiatry & the psychedelic drugs. Past, present & future

Cannabis sativa L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment

Sistema endocannabinoide y el rol del cannabis medicinal en el tratamiento de la espasticidad: una revisión narrativa

Contact Info

Product

Resources

About